P-157 A phase II study of XELOX and Cetuximab (Erbitux) as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (FLEET2)

Lignende værker

• Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
  af: Soda, Hitoshi, et al.
  Udgivet: (2015)
• Cetuximab (Erbitux)
  af: Bou-Assaly, W., et al.
  Udgivet: (2010)
• Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer
  af: Iwamoto, Shigeyoshi, et al.
  Udgivet: (2018)
• Severe Acneiform Eruption Induced by Cetuximab (Erbitux®)
  af: Lee, Jung Eun, et al.
  Udgivet: (2008)
• Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
  af: Nakamura, Masato, et al.
  Udgivet: (2016)